RAM
DFTX

Reflection Asset Management’s Definium Therapeutics DFTX Stock Holding History

Reflection Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-66
Closed -$898 – 336
2025
Q4 		$898 Buy
+66
New +$817 ﹤0.01% 491

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Reflection Asset Management's DFTX Position: Q1 2026 in Review

Reflection Asset Management sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 66 shares — an estimated $898 sold.

Reflection Asset Management first reported a position in DFTX in Q4 2025 and held it in 1 quarter. The position peaked at $898 in Q4 2025. 248 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Reflection Asset Management reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Reflection Asset Management sold 66 Definium Therapeutics shares in Q1 2026, an estimated $898.
  • Reflection Asset Management first reported a position in Definium Therapeutics in Q4 2025 and held it in 1 quarter.
  • Reflection Asset Management's Definium Therapeutics position peaked at $898 in Q4 2025.
  • 248 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Reflection Asset Management's 13F filing for Q1 2026, filed 26 Aug 2026.